In the figure, the top 8 targets are AKT1, TP53, STAT3, MAPK8, EGFR, TNF, CASP3, and PIK3CA, among which AKT1 has the highest degree (Figure 4), indicating that it may be a key target of GLP in the treatment of NASH. This evidence concerns the gene MAPK8 and metabolic dysfunction-associated steatohepatitis.